To comply with applicable regulation in Denmark, product-related media releases are removed from our website within three weeks of publication. They are available upon request. Please contact us here. News Category AllArticles of AssociationCompany AnnouncementsMedia Releases Year All202420232022202120202019 Sep 15, 2024 at 2:45 PM CEST Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial Download Sep 11, 2024 at 8:30 PM CEST Genmab A/S has published its Articles of Association Download Sep 10, 2024 at 10:07 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download Aug 26, 2024 at 6:26 PM CEST Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Download Aug 19, 2024 at 8:00 PM CEST TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Download Aug 16, 2024 at 3:00 PM CEST Genmab Announces Changes to its Executive Committee Download Aug 14, 2024 at 4:23 PM CEST Genmab A/S has published its Articles of Association Download Aug 13, 2024 at 8:53 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Download Aug 13, 2024 at 8:51 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download Aug 08, 2024 at 5:03 PM CEST Genmab Announces Financial Results for the First Half of 2024 Download Aug 08, 2024 at 5:01 PM CEST Genmab Updates 2024 Financial Guidance Download Aug 05, 2024 at 11:50 AM CEST Genmab Takes Full Control of Acasunlimab Development Program Download Jul 17, 2024 at 12:25 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 Download Jun 28, 2024 at 8:00 AM CEST Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma Download Jun 27, 2024 at 11:00 PM CEST Completion of Share Buy-back Program Download Download Jun 27, 2024 at 1:03 AM CEST EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Download Jun 24, 2024 at 3:56 PM CEST Transactions in Connection with Share Buy-back Program Download Download Jun 19, 2024 at 3:28 PM CEST Genmab A/S has published its Articles of Association Jun 18, 2024 at 8:45 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download Jun 17, 2024 at 3:33 PM CEST Transactions in Connection with Share Buy-back Program Download Download Jun 17, 2024 at 2:33 PM CEST Genmab A/S has published its Articles of Association Jun 12, 2024 at 9:45 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab Download Jun 11, 2024 at 8:51 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Download Jun 10, 2024 at 4:19 PM CEST Transactions in Connection with Share Buy-back Program Download Download Jun 05, 2024 at 6:51 PM CEST Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference Download
Sep 15, 2024 at 2:45 PM CEST Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial Download
Sep 10, 2024 at 10:07 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download
Aug 26, 2024 at 6:26 PM CEST Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference Download
Aug 19, 2024 at 8:00 PM CEST TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Download
Aug 13, 2024 at 8:53 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Download
Aug 13, 2024 at 8:51 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download
Jul 17, 2024 at 12:25 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 Download
Jun 28, 2024 at 8:00 AM CEST Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma Download
Jun 27, 2024 at 1:03 AM CEST EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Download
Jun 24, 2024 at 3:56 PM CEST Transactions in Connection with Share Buy-back Program Download Download
Jun 18, 2024 at 8:45 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise Download
Jun 17, 2024 at 3:33 PM CEST Transactions in Connection with Share Buy-back Program Download Download
Jun 12, 2024 at 9:45 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab Download
Jun 11, 2024 at 8:51 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Download
Jun 10, 2024 at 4:19 PM CEST Transactions in Connection with Share Buy-back Program Download Download
Jun 05, 2024 at 6:51 PM CEST Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference Download